厄帕他替尼治疗敏感部位特应性皮炎的疗效评价。

IF 3 3区医学 Q2 DERMATOLOGY

Dermatology Pub Date : 2025-04-23 DOI:10.1159/000545227

Niccolò Gori, Marco Galluzzo, Andrea Chiricozzi, Teresa Grieco, Camilla Chello, Filomena Russo, Ersilia Tolino, Flavia Pigliacelli, Anna Maria Mazzotta, Marina Talamonti, Claudia Paganini, Giacomo Caldarola, Barbara Cocuroccia, Flaminia Antonelli, Luisa Boeti, Domenico Giordano, Luca Bianchi, Clara De Simone, Giovanni Pellacani, Ketty Peris

{"title":"厄帕他替尼治疗敏感部位特应性皮炎的疗效评价。","authors":"Niccolò Gori, Marco Galluzzo, Andrea Chiricozzi, Teresa Grieco, Camilla Chello, Filomena Russo, Ersilia Tolino, Flavia Pigliacelli, Anna Maria Mazzotta, Marina Talamonti, Claudia Paganini, Giacomo Caldarola, Barbara Cocuroccia, Flaminia Antonelli, Luisa Boeti, Domenico Giordano, Luca Bianchi, Clara De Simone, Giovanni Pellacani, Ketty Peris","doi":"10.1159/000545227","DOIUrl":null,"url":null,"abstract":"Introduction: The treatment of atopic dermatitis (AD) affecting sensitive areas (head and neck, hands, and genitalia) remains a significant challenge, even with the advent of the current range of biologic therapies. Upadacitinib, a selective inhibitor of the JAK1 enzyme, showed promising results in the treatment of AD located in sensitive areas in clinical trials. The aim of this multicenter observational study was to better characterize the effectiveness of upadacitinib in sensitive areas, using specific clinimetric tools.Methods: In this multicenter observational retrospective and prospective study, we enrolled 74 adult patients (41 women and 37 men, with a mean age of 33.8 years), affected by moderate to severe AD with the involvement of at least one sensitive area, treated with upadacitinib with at least 16 weeks.Results: Over the course of the 52-week study period, upadacitinib demonstrated remarkable efficacy in the reduction of AD symptoms and associated clinical manifestations in sensitive areas.Conclusion: Our study demonstrates a significant benefit for patients with AD affecting sensitive areas when treated with upadacitinib, supporting its use first-line therapeutic choice for this specific subset of patients.","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-7"},"PeriodicalIF":3.0000,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of Upadacitinib Efficacy in the Treatment of Atopic Dermatitis of Sensitive Areas.\",\"authors\":\"Niccolò Gori, Marco Galluzzo, Andrea Chiricozzi, Teresa Grieco, Camilla Chello, Filomena Russo, Ersilia Tolino, Flavia Pigliacelli, Anna Maria Mazzotta, Marina Talamonti, Claudia Paganini, Giacomo Caldarola, Barbara Cocuroccia, Flaminia Antonelli, Luisa Boeti, Domenico Giordano, Luca Bianchi, Clara De Simone, Giovanni Pellacani, Ketty Peris\",\"doi\":\"10.1159/000545227\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: The treatment of atopic dermatitis (AD) affecting sensitive areas (head and neck, hands, and genitalia) remains a significant challenge, even with the advent of the current range of biologic therapies. Upadacitinib, a selective inhibitor of the JAK1 enzyme, showed promising results in the treatment of AD located in sensitive areas in clinical trials. The aim of this multicenter observational study was to better characterize the effectiveness of upadacitinib in sensitive areas, using specific clinimetric tools.Methods: In this multicenter observational retrospective and prospective study, we enrolled 74 adult patients (41 women and 37 men, with a mean age of 33.8 years), affected by moderate to severe AD with the involvement of at least one sensitive area, treated with upadacitinib with at least 16 weeks.Results: Over the course of the 52-week study period, upadacitinib demonstrated remarkable efficacy in the reduction of AD symptoms and associated clinical manifestations in sensitive areas.Conclusion: Our study demonstrates a significant benefit for patients with AD affecting sensitive areas when treated with upadacitinib, supporting its use first-line therapeutic choice for this specific subset of patients.\",\"PeriodicalId\":11185,\"journal\":{\"name\":\"Dermatology\",\"volume\":\" \",\"pages\":\"1-7\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-04-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000545227\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000545227","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

影响敏感区域（头颈部、手部和生殖器）的特应性皮炎（AD）的治疗仍然是一个重大挑战，即使目前出现了一系列生物疗法。最近，JAK1酶的选择性抑制剂Upadacitinib已被批准用于治疗中度至重度特应性皮炎（AD），并在治疗位于敏感部位的AD方面观察到令人满意的结果。这项多中心观察性研究的目的是使用特定的临床测量工具，更好地表征Upadacitinib在敏感区域的有效性。我们招募了74名成年患者（41名女性和37名男性，平均年龄33.8岁），这些患者受中度至重度AD的影响，至少涉及一个敏感区域。他们接受Upadacitinib治疗至少16周。在52周的研究期间，Upadacitinib在减轻AD症状和敏感区域相关临床表现方面表现出显著的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Evaluation of Upadacitinib Efficacy in the Treatment of Atopic Dermatitis of Sensitive Areas.

Introduction: The treatment of atopic dermatitis (AD) affecting sensitive areas (head and neck, hands, and genitalia) remains a significant challenge, even with the advent of the current range of biologic therapies. Upadacitinib, a selective inhibitor of the JAK1 enzyme, showed promising results in the treatment of AD located in sensitive areas in clinical trials. The aim of this multicenter observational study was to better characterize the effectiveness of upadacitinib in sensitive areas, using specific clinimetric tools.

Methods: In this multicenter observational retrospective and prospective study, we enrolled 74 adult patients (41 women and 37 men, with a mean age of 33.8 years), affected by moderate to severe AD with the involvement of at least one sensitive area, treated with upadacitinib with at least 16 weeks.

Results: Over the course of the 52-week study period, upadacitinib demonstrated remarkable efficacy in the reduction of AD symptoms and associated clinical manifestations in sensitive areas.

Conclusion: Our study demonstrates a significant benefit for patients with AD affecting sensitive areas when treated with upadacitinib, supporting its use first-line therapeutic choice for this specific subset of patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Dermatology 医学-皮肤病学

CiteScore

6.40

自引率

2.90%

发文量

审稿时长

1 months

期刊介绍： Published since 1893, ''Dermatology'' provides a worldwide survey of clinical and investigative dermatology. Original papers report clinical and laboratory findings. In order to inform readers of the implications of recent research, editorials and reviews prepared by invited, internationally recognized scientists are regularly featured. In addition to original papers, the journal publishes rapid communications, short communications, and letters to ''Dermatology''. ''Dermatology'' answers the complete information needs of practitioners concerned with progress in research related to skin, clinical dermatology and therapy. The journal enjoys a high scientific reputation with a continually increasing impact factor and an equally high circulation.